The present study focused on inhibition of HSV-1 and -2 replication and pathogenesis in vitro and in vivo, through the selective targeting of the envelope glycoprotein D. Firstly, a human monoclonal antibody (Hu-mAb#33) was identified that could neutralise both HSV-1 and -2 at nM concentrations, including clinical isolates from patients affected by different clinical manifestations and featuring different susceptibility to acyclovir in vitro. Secondly, the potency of inhibition of both infection by cell-free viruses and cell-to-cell virus transmission was also assessed. Finally, mice receiving a single systemic injection of Hu-mAb#33 were protected from death and severe clinical manifestations following both ocular and vaginal HSV-1 and -2 lethal challenge. These results pave the way for further studies reassessing the importance of HSV entry as a novel target for therapeutic intervention and inhibition of cell-to-cell virus transmission.
Introduction
The global prevalence of HSV-1 is approximately 67%. While the prevalence of HSV-2 is lower, it still infects 19.2 million people every year. HSV-2 is a particular problem in Africa, with at least 3.4 million infections in women (Looker et al., 2015) . Severe manifestations in a small proportion of HSV infections presents a significant healthcare burden. Despite the availability of effective drugs, clinical isolates can be resistant to both first and second line therapies (acyclovir (ACV) and foscarnet (FOS), respectively) (Andrei and Snoeck, 2013; Schubert et al., 2014) . The observed prevalence of ACV-resistant HSV in immunocompetent individuals is 0.1e0.6%, while in immunocompromised patients the prevalence of ACV resistance increases to 4.3e14% (Gilbert et al., 2002; Lascaux et al., 2012) . Moreover, it has been observed that in 61% of HIV infected patients co-infected with ACV-resistant HSV and treated with FOS, the HSV strain developed resistance to FOS (Danve-Szatanek et al., 2004; Lascaux et al., 2012; Safrin et al., 1994) . All of the available drugs display nephrotoxicity when administered at high doses, thus limiting their clinical use in patients with impaired kidney function (Superti et al., 2008; Whitley and Roizman, 2001) . Novel alternative or synergistic therapies are needed (Clementi et al., 2016) , especially for the management of high risk patients such as new-borns, immunocompromised individuals or post-transplant patients (Cherpes et al., 2012; Grinde, 2013; Whitley, 2006) . In this context HSV entry may represent an additional therapeutic target. Monoclonal antibodies (mAbs) are a particularly versatile class of virus entry inhibitors and have the advantage that their different engineered formats (single chain fragment variable (scFv), Fab fragment and whole-IgG) can fulfil both pharmacokinetic and pharmacodynamic needs while retaining their specificity for the target antigen (Jefferis, 2012; Marasco and Sui, 2007) . In addition, the use of human Abs generally reduces the risk of eliciting antidrug antibodies after administration in humans Presta, 2006) . To date, several anti-HSV neutralising mAbs have been described (Berdugo et al., 2012; Burioni et al., 1994; Chen et al., 2004; Krawczyk et al., 2013; Lee et al., 2013; Nicola et al., 1998) , but only a few are human-derived and inhibition of HSV infection by different engineered antibody formats (Fab, scFv, IgG) has never been compared. In the present study an anti-HSV HumAb (mAb#33) was isolated and its different formats (Fab#33, scFv#33, IgG#33) were tested for their ability to inhibit virus infection both before, and after virus entry (post-virus entry assays) using clinical isolates representing HSV-1 and HSV-2 with differing susceptibility to ACV. Finally, the mAb#33 format with the greatest potency in vitro was also tested in vivo using single systemic administrations against vaginal or ocular infections with HSV-1 or HSV-2.
Materials and methods

Cells and viruses
Vero E6 (Vero C1008, clone E6 -A TCC ® CRL-1586TM) and HEK
293T (ATCC ® CRL-1586TM) cells were cultured in Dulbecco's Modified Eagle Medium (DMEM) containing 10% (v/v) fetal bovine serum (FBS). The laboratory strains HSV-1 HF (ATCC ® VR-260™)
and HSV-2 MS (ATCC ® VR-540™) were used. Clinical isolates were kindly provided by Dr. R. Santangelo, Department of Microbiology, Universit a Cattolica del Sacro Cuore of Rome, Italy. The HSV-1 LV strain has been previously described (Tognon et al., 1985) .
Mice
Female C57BL/6N mice, eight weeks of age, were purchased from Charles River Laboratories (Sulzfeld, Germany) and housed and bred in a biosafety level 3 animal facility. Animals were maintained on 12/12-h dark/light cycle. Animal experiments were reviewed and approved by OPBA (Organismo Preposto al Benessere Animale) Universit a di Pisa and Ministero della Salute (Permit Number: n 603/2015-PR) by the responsible authority DGSAF (Direzione Generale della Sanit a Animale e dei Farmaci Veterinari), according to Italian Welfare Act (D.lgs. 26/2014. Art.31) and European regulations (2010/63/EU).
Generation and production of Fab#33
Fab#33 was selected using phage-display (Johnston et al., 2011; Solforosi et al., 2012) . Briefly, a phagemid library was constructed from peripheral B cells of a donor showing strong serum IgG ELISA reactivity against both HSV-1 and -2 isolates. Fab#33 was selected against HSV-1 and -2 infected Vero E6 cells after deselection against uninfected cells, and subsequently affinity purified through a GammaBind Sepharose (GE Healthcare) column with goat antihuman IgG Fab (ThermoFisher Scientific).
Other antibodies
The anti-HSV gD positive neutralisation control human Fab AC-8 (Burioni et al., 1994) was synthesised using its previously published amino acid sequence (Berdugo et al., 2012) . Anti-HCV E2 e137 human mAb was used as negative experimental control (Perotti et al., 2008) .
scFv#33 and IgG#33
scFv#33 was constructed using overlapping primers with the 15-amino acid (Gly 4 Ser) 3 flexible hinge region respectively at 3 0 and 5 0 , and purified following the previously described protocols. The IgG#33 format was designed in our laboratory using an IgG1 constant region. Large-scale production was performed by GenScript ® using the MamPower service. Briefly, target DNA were designed, synthesised and subcloned into pTT5 vectors for co-transfection and expression in HEK 293-E6 cells. The cell supernatant was collected and affinity purified.
Neutralisation assays and post-entry inhibition assays
The biological activity of mAbs was determined in vitro using three different strategies.
Plaque assay
Serially diluted preparations of the different antibody formats were incubated with 100 plaque forming units (PFU) of virus (1 h at 37 C) in DMEM. Antibody-virus mixture was applied to Vero E6 monolayers. After 2 h, medium was replaced with complete DMEM with 2% FBS and 1% Agarose (BD) and plates were incubated for 46 h. Cells were then fixed and stained.
IN Cell Analyzer System analysis
Different antibody concentrations were incubated with 200 TCID 50 of virus for 1 h at 37 C. Virus/antibody mixture was applied to Vero E6. After 2 h medium was replaced with complete DMEM with 2% FBS and plates were incubated for 21 h. Cells were fixed and stained with anti-HSV1þHSV2 gD murine antibody [2C10] (ab6507, Abcam) and goat anti-mouse IgGeFITC antibody (F0257, Sigma-Aldrich). Hoechst 33258 (Sigma-Aldrich) was used for nuclear staining. IN Cell Analyzer System allowed high-throughput acquisition and analysis was performed using IN Cell Investigator Software (Galluccio et al., 2014; Ranade et al., 2014) .
Post-entry assay
The post-entry assay was adapted from previous studies (De Logu et al., 1998; Krawczyk et al., 2013) . Confluent monolayers of Vero E6 were infected with 100 PFU of virus. After 20 min of adsorption at 37 C, the virus was removed. Cells were then incubated for 46 h in DMEM containing 2% FBS and 1% Agarose in the presence of different mAb concentrations. Cells were fixed and stained. Images were acquired at 5-fold magnification. Viral plaques were counted and areas measured in silico using ImageJ 1.50c4 software (Rasband, ImageJ, U.S.N.I.H., Bethesda USA, http://imagej. nih.gov/ij/).
Cytofluorimetric binding assays
The binding activity of Fab#33 was assayed using HEK 293T cells transfected with glycoprotein D from HSV-1 HF (gD1) as described in the Supplementary Materials. After centrifugation, cells were fixed with 4% paraformaldehyde and incubated for 30 min at room temperature with Fab#33 in presence or absence of the competitor anti-HSV gD AC-8 Fab (Burioni et al., 1994) . Additionally, unrelated anti-HCV E2 e137 Fab (Perotti et al., 2008) 
In vivovirus titration
In vivo titration via vaginal challenge of HSV-2 MS viral stock was performed in mice at eleven weeks of age, with their oestrous cycles synchronised as described (Chiuppesi et al., 2012; Teepe et al., 1990) . Ten-fold dilutions of the viral stocks in DMEM (50 mL) were pipetted intravaginally under general anaesthesia.
HSV-1 LV and HSV-2 MS viral stocks were used for in vivo titration via ocular challenge: under general anaesthesia, the right cornea was scarified and 5 mL of DMEM (2% serum) containing 10-fold dilutions of the viral stocks was applied. The animals were then examined daily for clear signs of infection. The lethal dose 50 (LD 50 ) of both viruses was assessed for each infection protocol (Fig. S1 ). The doses of both viruses for the different infection protocols were determined by observation of irreversible symptoms at day 8 post infection (p.i.) for HSV-2 MS (both for vaginal and ocular challenge) and at day 13 p.i. for HSV-1 LV. Mice that recovered from disease were followed up for 20 days p.i. and no relevant differences in their conditions, nor delayed onset of clinical symptoms were observed.
2.9. IgG#33 prophylactic and therapeutic activity against vaginal challenge 2.9.1. In vivo virus infections and treatments Eleven-week-old female mice were infected with 50 mL of HSV-2 MS (5 Â 10 7 PFU) diluted in DMEM. Mice received 100 mL of IgG#33 (5 or 15 mg/kg) diluted in PBS through the lateral tail vein as a single dose 24 h before, or 30 min after vaginal challenge. Anti-HCV IgG e137 (15 mg/kg) was used as negative control. Groups consisted of 7 mice each; animals were sacrificed on day 8 to avoid unnecessary suffering. Animal experiments were approved by Pisa University and Ministry of Health, accordingly to national and European regulations (2010/63/EU).
Clinical disease scoring
Severity of genital lesions was scored as previously described (Chiuppesi et al., 2012) . Animals were scored at baseline and at daily intervals. Clinical scores were reported starting from the onset of symptoms to the end of protocol (day 5e8).
Vaginal lavage viral titres
At 48 h post-challenge mice were anesthetised, the vaginas were flushed with 50 mL of 1X PBS and the lavages stored at À80 C. Subsequently, 10 mL of vaginal lavage were applied to Vero E6 cell monolayers. After 2 h, the inoculum was replaced with complete DMEM with 2% FBS and plates incubated for 21 h. Cells were fixed, stained and analysed using IN Cell Analyzer.
2.10. IgG#33 therapeutic activity against ocular challenge 2.10.1. In vivo virus infections and treatments Under general anaesthesia, the right cornea was scarified (Berdugo et al., 2012) . 5 mL of HSV-1 LV (5 Â 10 4 PFU) or HSV-2 MS (5 Â 10 5 PFU) diluted in DMEM was applied to scarified cornea.
Eleven-week-old female mice received 100 mL of IgG#33 (15 mg/kg) i.v., or IgG e137 (15 mg/kg) as controls, diluted in 1X PBS via lateral tail vein as a single dose 30 min after infection. All groups consisted of 5 mice each and all HSV-1 infected mice were sacrificed on day 13, while HSV-2 infected mice were sacrificed on day 8 to avoid unnecessary suffering.
Clinical disease scoring
The severity of ocular disease was scored as previously described (Berdugo et al., 2012) . Animals were scored at baseline and at daily intervals.
Tear film viral titres
At 2nd and 7th day p.i. mice were anesthetized and infected corneas were flushed pipetting and recollecting 10 mL of DMEM containing 2% serum (Berdugo et al., 2012) . The tear film content was added to 190 mL of medium, stored at À80 C and analysed as for vaginal lavages. Furthermore, 10 mL of tear film samples were used for viral DNA extraction (QIAGEN) and genomic copies quantified using ELITeMGB ® Kit (ELITechGroup) for Real-Time PCR analysis.
Tissue preparation and immunohistochemistry
Kidneys and eyes from each group of mice were dissected, fixed and mounted in Killik (Bio-Optica) at À80 C for cryosectioning. Hoechst was used for nuclear staining. Slides were observed at 63-and 10-fold magnification.
Statistical analysis
All data analyses and statistics were performed using GraphPad PRISM ® (GraphPad Software, San Diego California USA, www.
graphpad.com). One-way ANOVA was performed with repeated measures followed by Bonferroni post-test for the evaluation of plaque areas inhibitory activity of the different Hu-mAb#33 engineered formats. The same test was used for the comparison of reduction of plaque number of the different mAb engineered formats in post-entry assays. Kaplan-Meier survival curves were compared using the log-rank (Mantel-Cox) test considering p ¼ 0.05 as threshold for statistical significance. Two-way ANOVA with Bonferroni post-tests were used to perform statistical comparisons between the different mean disease clinical scores observed for each treated mouse cohort. One-way ANOVA followed by Kruskal-Wallis test was used for statistical analysis of titrations of vaginal lavages. T-test followed by Welch's correction was used for statistical analysis of data generated by titres and genomic copies quantification assays of tear film samples. See Supplementary for fully detailed Material and Methods.
Results
In vitro experiments were initially performed to inform the selection of antibody format to be evaluated in animal infection models. The Hu-mAb#33 was produced in three different molecular formats: Fab, scFv and IgG. After identification of the virus glycoprotein recognised by Hu-mAb#33, all three formats were first tested for their ability to neutralise both HSV-1 and -2, including clinical isolates with different susceptibility to ACV in in vitro phenotypic assays. Their inhibitory activity was tested in a newly developed post-entry assay performed at 37 C, allowing virus entry into target cells to test the ability of scFv#33, Fab#33 and IgG#33 to inhibit virus replication and even more importantly, cell-to-cell transmission, when added after virus infection in semisolid culture medium. Based on the lower IC 50 and potent postentry inhibitory activity compared to other molecular formats, Hu-mAb#33 IgG was chosen for testing in vivo its capability to protect mice from lethal virus vaginal and ocular HSV-1 and -2 virus challenge.
Generation of an anti-HSV-1 and HSV-2 cross-reactive Hu-mAb and target identification
A human mAb was generated as Fab fragment (Fab#33) using optimised biopanning procedures from peripheral B-lymphocytes of a donor showing strong serum IgG reactivity in ELISA against HSV-1 and -2 isolates (Fig. S2 ). Fab#33 specifically recognised HSV-1 HF-and HSV-2 MS-infected cells (Fig. S3A ). Western-blotting (WB) analysis on purified HSV-1 particles ( Fig. S4A ) and indirect immunofluorescence (IIF) analysis on cells transfected with HSV-1 HF gD or HSV-1 HF gB (Fig. S4B) were also performed. Both assays demonstrated the specific binding of Fab#33 only to gD-transfected cells.
Evaluation of anti-HSV neutralising activity
Fab#33 neutralising activity was assessed by plaque reduction assays (PRA) against both HSV-1 and -2 (Fig. S5 ). The IC 50 values against HSV-1 HF and HSV-2 MS were 0.76 mg/mL and 0.118 mg/mL, respectively. Fab#33 potency was also determined by microneutralisation assay followed by automated IIF counting, with IC 50 values of 0.612 mg/mL for HSV-1 HF and 0.135 mg/mL for HSV-2 MS ( Table 1 ). The micro-neutralisation assay reduced experimental variability and accurately evaluated Fab IC 50 due the increased range of experimental conditions and number of replicates. Both assays confirmed that Fab#33 neutralises both HSV types at low nanomolar concentrations: 2.7 nM (HSV-2 MS) and 12.24 nM (HSV-1 HF).
Evaluation of post-entry inhibitory activity
The ability of Fab#33 to inhibit replication of HSV-1 and -2 even after infection was evaluated using a specifically adapted PRA in which the Fab#33 was dissolved in low concentration DMEM-agar medium (Krawczyk et al., 2013) . Both number and area of plaques were quantified. Fab#33 reduced the number of HSV-1 HF plaques by 18.92% at 50 mg/mL and HSV-2 MS plaques by 57% at 200 mg/mL (Fig. 1A) . Fab#33 reduced the mean plaque areas of HSV-2 MSinfected cells by 43.5% at 100 mg/mL, whereas no significant reduction in plaque areas was observed on HSV-1 HF-infected cells (p > 0.05) (Fig. 1B) . Post-entry activity of Fab#33 was also compared with that of anti-HSV Hu-Fab AC-8, which was previously described to neutralise both HSV-1 and -2 (Berdugo et al., 2012; Burioni et al., 1994; De Logu et al., 1998) . No significant differences between the two Fabs were observed in reduction of plaque number for HSV-2 MS infection (p > 0.05), while only Fab#33 slightly decreased the number of plaques on HSV-1 HF infected cells (p < 0.05) (Fig. 1A) . No differences were observed in plaque area reduction for HSV-1 HF. Interestingly, Fab#33 had greater potency than AC-8 against HSV-2 MS (43.5% reduction by 100 mg/mL Fab#33, vs 24.3% reduction by 200 mg/mL AC-8) (Fig. 1B) . A competition assay between the two Fabs was also performed by FACS analysis of cells transfected with gD1. Dose-dependent competition was observed at a higher AC-8 concentration (10 mg/mL) using Fab#33 at low concentration (1.5 mg/mL) for all the tested AC-8 concentrations (Fig. 1C) .
Evaluation of in vitro activity of different engineered HumAb#33 formats: scFv#33, Fab#33 and IgG#33
To evaluate the biological activity of different antibody formats, scFv#33, Fab#33 and IgG#33 formats were produced and tested for their ability to bind, neutralise and inhibit HSV post-entry replication. Both IgG#33 and scFv#33 bound to cells infected with HSV-1 HF or HSV-2 MS isolates (Fig. S3B) . Comparison of their neutralising activity revealed that IgG#33 possessed IC 50 s of 1.092 mg/mL (HSV-1 HF) and 0.731 mg/mL (HSV-2 MS) ( Table 1, Fig. S6 ). No appreciable neutralising activity was observed for scFv#33.
Inhibition of HSV infection after virus entry by scFv#33 and IgG#33 was then assessed using the adapted PRA (Figs. 2, S7, S8 ). In this case, scFv#33 in semi-solid medium inhibited the number of infectious events by 29.6% on HSV-2 MS infected cells at 200 mg/mL and by 24.2% at 50 mg/mL (Fig. 2B) . scFv#33 inhibited the number of HSV-1 infection events by 22.16% at 50 mg/mL (Fig. 2A) . In contrast, IgG#33 strongly inhibited HSV-2 MS infection events in a dosedependent manner, from 93% inhibition at 100 mg/mL, to 40% at the lowest tested concentration (6 mg/mL) (Fig. 2B) . No significant inhibition of viral infection (6.57%) was observed for IgG#33 format against HSV-1 HF at the highest concentration attempted (25 mg/ mL) ( Fig. 2A) . Both scFv#33 and IgG#33 formats potently reduced HSV-2 MS plaque area in a dose-dependent manner (Figs. 2B and S8B). scFv#33 inhibited virus spreading by 99.8% at 200 mg/mL and plaque area was inhibited by 90% at 100 mg/mL and by 63.2% at 12.5 mg/mL. IgG#33 almost eliminated plaques (98.2% reduction) of HSV-2 MS at 100 mg/mL and by 44.2% at 6 mg/mL scFv and IgG formats inhibited HSV-1 HF virus cell-to-cell spread by 91.7% at 50 mg/mL and 94.2% at 25 mg/mL respectively ( Figs. 2A and S8A ). The three mAb formats were also tested in a post virus attachment assay (Fig. S9) . The adsorption performed at 4 C, allowed docking of virus with cell receptors but impaired cell entry until the switch to 37 C performed after the 4 C addition of antibodies. Virus entry inhibition was observed for all tested antibody formats, with no significant differences between the different formats for HSV-2 MS. Conversely, both IgG and scFv demonstrated better HSV-1 HF inhibition compared to the Fab#33.
Evaluation of IgG#33 anti-HSV activity against HSV-1 and -2 clinical isolates
Cross-protection conferred by IgG#33 was evaluated against clinical isolates from patients with different clinical manifestations: #1 (oral lesions), #8 (pharyngeal swab), #7 (bronchoalveolar lavage), #11 (labial vesicles), #LV (neurotropic strain (Tognon et al., 1985) ) for HSV-1, and #18 (cutaneous lesions), #21 (vaginal discharge) #25 (vaginal lesions), #26 (cutaneous lesions) and #28 (cutaneous lesions) for HSV-2. All the isolates featured different susceptibility to ACV (Fig. S10) . As depicted by Table 2 and Fig. S11 , IgG#33 potently neutralised all tested clinical isolates at very low IC 50 s.
IgG#33 post-entry activity was evaluated against LV and #26 virus isolates (Fig. 3) . IgG#33 inhibited the number of plaques of HSV-1 LV by 76.85% at 25 mg/mL (p < 0.05), and by 45.68% at 3 mg/ mL (p < 0.05) (Fig. 3A) . IgG#33 had greater activity against HSV-2 #26, resulting in 94.18% inhibition at 100 mg/mL and 52.13% inhibition at 10 mg/mL (p < 0.05) (Fig. 3B) . IgG#33 reduced HSV-2 #26 plaque areas by 98% at 100 mg/mL and by 75.3% at 25 mg/mL on HSV-1 LV.
Prophylactic and therapeutic activity of IgG#33 against vaginal HSV-2 challenge
A single systemic injection of IgG#33 (5 mg/kg or 15 mg/kg) into ) and upper and lower 95% CI from mean (above each column, the percentages indicating reduction in plaque area compared to virus control is indicated). Hu-mAb#33 engineered molecular formats tested against HSV-1 HF (A) and HSV-2 MS (B). Statistically significant p values are obtained by comparing mAb#33 to mAb mock control (black asterisks), and Fab#33 to IgG#33 or scFv#33 (red asterisks) (****p < 0.0001, ***p < 0.001, **p < 0.01, *p < 0.05). the lateral tail vein was performed 24 h prior, or 30 min after, HSV-2 MS infection (30 min are sufficient for virus entry (Vahlne et al., 1980) ). Kaplan-Meier survival curves (Fig. 4A) revealed that both IgG#33 dosages conferred 100% protection from death (7/7 mice survived) 8 days p.i., compared to control groups in both settings (5/7 mice died; 71.43% mortality) (p ¼ 0.0075). No statistically significant difference in mortality at day 8 p.i. (p ¼ 0.1356) was observed between negative control IgG treated mice (2/7 mice died) and the infection control (5/7 mice died) in prophylactic protocol, while in a therapeutic setting 6/7 mice died in the unrelated IgG mock control group (p ¼ 0.0019). The mean clinical disease scores revealed that both IgG#33 single doses strongly inhibited clinical manifestation of HSV-2 infection compared to infection and mock controls (Fig. 4B) . Clinical scores were reported from the onset of symptoms to the end of protocol (day 5e8). Mean clinical disease scores of the prophylactic protocol were: 1.571 to 2.857 for HSV-2 infection control group; 0.643 to 2.114 for the group receiving control IgG; 0.143 to 0.286 for IgG#33 at 5 mg/kg; and 0 to 0.571 for the group receiving 15 mg/kg IgG#33. Mean clinical disease scores of therapeutic protocols were: 1.571 to 2.857 for HSV-2 infection control group; 1.357 to 3.643 for the group receiving control IgG; 0.143 to 0.286 for the group receiving 5 mg/ kg IgG#33 and 0.143 to 0.357 for the group receiving 15 mg/kg IgG#33. Both IgG#33 concentrations significantly reduced mean disease score compared to virus infection control starting from day 6 p.i. (p < 0.05) as well as to the group receiving the unrelated IgG (p < 0.01). Mice treated with IgG#33 in both experimental settings did not present clinically relevant manifestations of HSV-2 infection, whereas symptoms in control animals spanned from erythema and ulcers to nervous system involvement (Fig. 4C) . Finally, vaginal lavages collected 48 h p.i. from the different mouse cohorts were tested for their infectious viral load using cell-based infection assays (Fig. 4D) . A significant reduction in viral load was observed in lavages collected from IgG#33-treated groups compared to untreated groups (p < 0.01). Titres (FFU/mL) detected in vaginal lavages of the prophylactic protocol mice were: 7. Fig. 4 .
Therapeutic activity of IgG#33 against HSV-1 and HSV-2 ocular challenge
A single systemic administration of IgG#33 (15 mg/kg) was performed 30 min after ocular infection with HSV-1 LV (neurotropic strain) or HSV-2 MS, fully protecting mice from death (Fig. 5A ). All HSV-1 infected mice were sacrificed on day 13, while HSV-2 infected mice were sacrificed on day 8 to avoid unnecessary suffering. Administration of IgG#33 conferred 100% protection against HSV-1 LV (7/7 mice alive at 13 days p.i.), in contrast to 71.43% mortality rate (5/7 mice died) observed for the control group (p ¼ 0.007). IgG#33 fully protected mice (7/7 alive) against HSV-2 MS compared to controls (p ¼ 0.022 vs virus infection control, and p ¼ 0.007 vs unrelated IgG). No differences were observed between virus control and a group receiving an unrelated IgG (p ¼ 0.590). Mean clinical disease scores (Berdugo et al., 2012) were evaluated between days 1e8 p.i. (Fig. 5B) . For the HSV-1 LV protocol, mean symptom scores were evaluated between days 1e13 p.i.: 0 to 3.714 for virus control group; 0 to 4.571 for the group receiving unrelated IgG and 0 to 0.143 for IgG#33-treated mice, indicating almost complete protection conferred by IgG#33 from ocular HSV-1 infection compared to controls (p < 0.001 from day 8). The mean clinical scores of HSV-2 MS infections were: 0 to 3.929 for the virus control group; 0 to 4.643 for the mice receiving unrelated IgG, and 0.071 to 0.214 for IgG#33-treated mice. Mice receiving IgG#33 were significantly protected from HSV-related severe disease compared to controls. Mice receiving IgG#33 occasionally developed milder symptoms after HSV-infection from which they recovered completely. In contrast, control mice developed severe movement impairment indicating neural involvement and severe HSV ocular symptoms (Fig. 5C ). Virus titres and quantification of HSV genome copies on tear films collected on days 2 and 7 p.i. were also evaluated ( Fig. 5D ): titres (FFU/mL) in tear samples of mice challenged with HSV-1 and receiving IgG#33 were 1.2 Â 10 4 at day 2, and 7.9 Â 10 2 at day 7; 4.3 Â 10 4 infected cells at day 2 and 1.4 Â 10 4 at day 7 were observed for the unrelated IgG tear samples. In mice infected with HSV-2, viral titres (FFU/mL) were: 5.4 Â 10 3 at day 2 and 1.1 Â 10 2 at day 7 for the cohort receiving IgG#33, and 1.2 Â 10 4 at day 2 and 1.5 Â 10 3 at day 7 for mice receiving control IgG. The same samples were also tested for the presence of HSV genomes. The median number of genome copies for mice challenged with HSV-1 were: 272.4 Nc(gEq/mL) at day 2 and 0 Nc(gEq/mL) at day 7 for mice receiving IgG#33; 1783 Nc(gEq/mL) at day 2 and 17.71 Nc(gEq/mL) at day 7 for mice receiving unrelated IgG. The median number of genome copies for mice challenged with HSV-2 were: 3241 Nc(gEq/mL) at day 2 and 0 Nc(gEq/mL) at day 7 for mice treated with IgG#33; 733.2 Nc(gEq/mL) at day 2 and 182.9 Nc(gEq/mL) at day 7 for unrelated IgG controls. Only IgG#33-treated mice completely cleared viral DNA and infectious viral load in tear films within 7 days for both HSV challenges. It was observed that the viral load was nearly undetectable in lavages of IgG#33-treated mice at day 7 p.i.. p values are reported in Fig. 5 .
Histological analyses
Four kidney anatomical compartments (capsule, cortex, medulla, pelvis) of mice treated with IgG#33 or unrelated control IgG after HSV ocular infections were analysed (Fig. 6A) . Mice receiving systemic IgG#33 presented normal tissue architecture for all the anatomic compartments, while mice receiving unrelated IgG control possessed altered tissue architecture, especially for medulla and pelvis. Apart from the capsule, tissues dissected from control mice were found to possess virus. Eyes dissected from IgG#33-treated mice and unrelated IgG control group were analysed, but no morphological differences were detectable. However, higher virus prevalence was detected in all compartments belonging to the HSV-1 control cohort (Fig. 6C ) compared to mice treated with IgG#33 ( Fig. 6B ), in which virus was restricted to its entry site (cornea) leaving the retina almost virus-free. Unfortunately, eye cryosections of mice challenged with HSV-2 MS were not properly compared due to tissue damage (Fig. S12 ).
Discussion
We investigated the anti-viral activity of an anti-gD human monoclonal antibody, mAb#33, both in vitro and in vivo. The mAb was engineered in three different antibody formats (scFv, Fab, IgG) to compare both neutralising activity and ability to inhibit cell-tocell transmission of HSV-1 and -2. This informed the choice of the best candidate to be administered in mice receiving lethal HSV challenge.
The neutralising activity of the Fab fragment was evaluated against HSV. The IC 50 s calculated for Fab#33 against HSV-1 and -2 are among the lowest described for Fabs of human origin. However, it is important to stress that potent neutralising activity does not always translate to potent in vivo efficacy (De Logu et al., 1998; Dimmock, 1993) . In the case of HSV infection, a low IC 50 is not the only anti-viral effect to be evaluated. It is well known that HSV infects cells both as cell-free virus and via cell-to-cell transmission. We evaluated the inhibitory activity of Fab#33 even when added to cells after virus entry, minimising the infection events due to cell free virus by adapting previously described post-virus entry assays (De Logu et al., 1998; Krawczyk et al., 2013) . The well characterised human anti-gD Fab AC-8 was included as a control (Berdugo et al., 2012; Burioni et al., 1994; De Logu et al., 1998; Sanna et al., 1996 Sanna et al., , 1999 2000; Zeitlin et al., 1996) . The post-entry assays revealed greater activity of Fab#33 in reducing both number and area of plaques for HSV-2 MS compared to that observed against HSV-1 HF, where the reduction in number of plaques was small and no reduction in plaque area occurred. The different activity of Fab#33 against the two virus laboratory strains might be due to the differences in the amino acid sequences of their gDs (Fig. S13) , potentially impairing Fab affinity. This is also consistent with the higher Fab#33 IC 50 against HSV-1 HF compared to that against HSV-2 MS. These results are similar to those observed for control mAb AC-8 against the same virus isolates, apart from the total lack of plaque number reduction by AC-8 Fab against HSV-1 HF strain. Additionally, the overall similar behaviour of Fab#33 and AC-8 in post-entry assays is also consistent with the reported IC 50 of AC-8 against HSV-2, lower than those described against HSV-1, as observed for Fab#33. This similarity is supported by the competition observed in FACS analyses performed between the two Fabs. The Fab#33 was engineered in other two antibody formats: scFv and whole IgG1. These were tested for both neutralising activity and inhibition of virus replication after virus entry. Unexpectedly, despite IgG#33 potently neutralised both HSV-1 and -2, the scFv format did not show any neutralising activity at the highest concentration tested. The same scFv potently reduced plaque areas in post-entry assays, for both HSV-1 and -2, but had limited impact on plaque number. Accordingly, IgG#33 potently inhibited plaque areas for both virus types, consistent with its potent inhibition of HSV-2 plaque number but discordant with its poor reduction of HSV-1 plaque number. As observed for the Fab format, the different activity in post-entry assays might be due again to differences between amino acid sequences of the gD of HSV-1 HF and HSV-2 MS, affecting the IgG binding affinity. The post-entry activity of the three antibody formats was then compared to their post virus attachment activity using previously-described procedures (Burioni et al., 1994) . This assay allowed assessment of the ability of the antibody formats to interfere with virus entry even after virus attachment to host-cell receptors. It is noteworthy that the assay performed at 4 C resulted in inhibitory activity by the scFv format against both virus types, in contrast to the standard neutralisation assays.
The exact processes underlying the mechanisms involved in mAb#33-mediated inhibition remain to be determined, but the inhibitory activity in post-entry assays of mAb#33 was robust and reproducible. A possible explanation for the observed effect might be the different steric hindrance of IgG compared to the Fab format. However, this is inconsistent with the behaviour of the scFv format in the same assay, which although lacking any neutralising activity possessed a strong activity in reducing plaque areas. An explanation of this paradoxical activity might be found in the possible mAb#33 interference of gD-mediated triggering of gB fusogenic activity. As highlighted by the complete lack of neutralising activity by the scFv#33, mAb#33 is probably directed against gD regions not directly involved in binding to cellular receptors. The observed neutralising activity of the Fab and the whole IgG formats may therefore only be an effect of increasing steric hindrance, inhibiting binding to the target cell. This specific feature was not directly addressed in the present study and deserves further investigation, as far as mAb#33 epitope definition is concerned.
Overall, the in vitro results and the interference with different stages of HSV spread suggested a potential application of mAb#33 in different HSV-related clinical manifestations. Given the higher in vitro efficacy against both HSV-1 and -2 laboratory strains of IgG#33 compared to its Fab and scFv antibody formats, we then tested its activity against different HSV-1 and -2 clinical isolates featuring different susceptibility to ACV. IgG#33 possessed potent neutralising activity against these clinical isolates and, surprisingly, resulted in an even stronger post-entry reduction of plaque number and greater inhibition of plaque areas against the tested isolates. Importantly, we observed that HSV-1 isolates, including the LV neurotropic isolate (Tognon et al., 1985) , are more susceptible to IgG#33 than the previously tested lab strain HSV-HF. These findings pave the way to the possible use of IgG#33 to treat diverse clinical HSV manifestations that are not susceptible to ACV treatment. Importantly, the IgG#33 target is completely different and unrelated to that of ACV, highlighting the potential for therapeutic coadministration with "classical" drugs for the treatment of patients suffering for drug nephrotoxicity.
Given the promising in vitro results, in vivo testing of IgG#33 was a logical progression of these studies. However, several mAbs able to neutralise HSV have been described so far. Most of them are directed against viral gD or gB and are of murine origin (D€ aumer et al., 2011; Lazear et al., 2012; Minson et al., 1986; Muggeridge et al., 1990; Nicola et al., 1998) , while fewer are of human origin (Burioni et al., 1994; Lee et al., 2013) . We decided to develop a human antibody to both minimise the risks of anti-IgG response and to avoid Ab-humanisation processes necessary for therapeutic mouse mAb administration. It is well known that repeatedly administering mAbs in humans may induce anti-idiotype and antiallotype antibodies. However, these adverse effects were documented mostly when administering animal-derived antibodies, whereas humanised mAbs were well tolerated (Ridker et al., 2017) . These side-effects do not occur for human monoclonal antibody administrations (De Logu et al., 1998; Knox et al., 1991) . For HSV the most protective and best characterised human/humanised mAbs recognise virus gD or gB of both HSV-1 and -2 (Berdugo et al., 2012; Krawczyk et al., 2013 Krawczyk et al., , 2015 Lee et al., 2013; Sanna et al., 1996; Zeitlin et al., 1996 Zeitlin et al., , 1998 . Among the most promising anti-gD mAbs are E317 and AC-8. The structural basis for recognition of gD antigen by the neutralising E317 Fab have been elucidated through co-crystallisation approaches. AC-8 is the only human antigD mAb tested on animals in different experimental settings. Topical administration of AC-8 in different antibody formats (Fab, F(ab 0 ) 2 , IgG1) was tested concomitantly to HSV-2 vaginal challenge (Zeitlin et al., 1996) , demonstrating for the first time the potential of topical passive immunisation with a human anti-gD mAb to both prevent lesions and reducing virus shedding. Another important advance was testing topical administration of AC-8 Fab against HSV-1 KOS corneal infection (Berdugo et al., 2012) . The Fab significantly limited disease and reduce virus titres within tear films, but was not as effective as trifluridine (TFT). Non-topical administration of anti-gD human IgG AC-8 protected SCID mice from both intra-cutaneous and ocular HSV-1 challenge (Sanna et al., 1995) . IgG AC-8 was administered intraperitoneally prior to, or after virus infection significantly prolonging mice survival. To date, intravenous systemic administration of human anti-gD antibodies has not been described.
Intravenous single administration of IgG#33 before or after HSV-1 and -2 ocular and vaginal lethal challenge was tested (Fern andez Gonz alez et al., 2013; James and Kimberlin, 2015) . In both prophylactic and therapeutic HSV-2 intravaginal infection experiments IgG#33 was injected at two doses compatible with possible clinical use (Glassman and Balthasar, 2014) . Both IgG doses fully protected mice from death in both experimental protocols. The main difference observed between these experiments was the greater reduction in virus titre in vaginal lavages from mice therapeutically treated with IgG#33, and the milder clinical signs compared to both control cohorts. However, in the prophylactic protocol the unrelated IgG partially protected mice from death at the end of experiments. Despite this, all the mice treated with the unrelated mAb control experienced greater disease progression in contrast with those treated with IgG#33, consistent with an increased virus titre measured in vaginal lavages of mice receiving the control IgG. An explanation for this partial protection from death but not from relevant clinical signs could be the immunogenic boost conferred to immunocompetent mice by the systemic administration of mAbs before the virus challenge. A single systemic IgG#33 intravenous administration also protected mice challenged with both HSV types via corneal scraping. The protection against HSV-1 ocular challenge conferred by systemic IgG#33 anti-gD mAb administration is consistent with previous studies using an anti-gB humanised antibody (Krawczyk et al., 2015) . IgG#33 protected mice from both death and severe HSV clinical manifestations over all experimental durations. Moreover, all mice receiving IgG#33 that presented milder disease completely recovered during the follow-up period.
Consistent with clinical scoring data, analysis of viral infectious load in tear films collected from the different mouse cohorts established that all mice receiving IgG#33 almost completely cleared both infectious HSV-1 and -2 virions and the presence of HSV genomes. These assumptions are consistent with microscopic observations of infected eye cryosections. Interestingly, in IgG#33-treated eyes, large amounts of virus were constrained to the primary infection site but very little virus was detected within the retina and adjacent eye tissue layers. In contrast, very high virus titres were present in the cornea, retina and other eye tissue layers within the eye receiving control IgG, indicating that the unrelated IgG could not block the spread of infection from cornea to adjacent tissues. This last observation is consistent with clinical depiction of eye disease scoring. Kidneys were dissected and stained to establish the presence of virus and tissue architecture in the different mice cohorts. Kidneys were chosen for immunohistochemistry because in this systemic infection model this evaluation provides insight related to antiviral/protective activity of the mAb during disseminated HSV infection. Kidneys were explanted without damaging tissue integrity. In contrast, infected brains completely lost their tissue consistency in our experimental setting, preventing sample cryosectioning. Confocal microscopy analysis of kidney cryosections revealed that only kidneys explanted from mouse receiving IgG#33 retained tissue integrity, with no evidence of virus in all internal kidney compartments. This observation is fully consistent with the total lack of severe systemic signs of HSV infection in mice treated with IgG#33.
Together, these observations confirmed the potential for IgG#33 as a therapeutic for HSV infection, considering also that in humans the Fc-mediated effects could further improve IgG efficacy allowing for example the recruitment of cellular immunity, such as CD8 þ T cells, which play pivotal roles in clearing HSV dissemination (Clementi et al., 2017; van Lint et al., 2004) . These data pave the way for further studies investigating either the ability of IgG#33 to inhibit virus reactivations in vivo, or the presence of gD epitopes eliciting in vivo an IgG#33-like antibody response (Belshe et al., 2012; Cairns et al., 2014; Clementi et al., 2017 Clementi et al., , 2013 .
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